Pacilio Massimiliano, Conte Miriam, Frantellizzi Viviana, De Feo Maria Silvia, Pisani Antonio Rosario, Marongiu Andrea, Nuvoli Susanna, Rubini Giuseppe, Spanu Angela, De Vincentis Giuseppe
Medical Physics Department, "Policlinico Umberto I" University Hospital, 00161 Rome, Italy.
Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Diagnostics (Basel). 2022 Jul 21;12(7):1763. doi: 10.3390/diagnostics12071763.
The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration of 131-sodium or potassium iodide. It is an effective tool used for the irradiation of thyroid remnants, microscopic DTC, other nonresectable or incompletely resectable DTC, or all the cited purposes. Dosimetry represents a valid tool that permits a tailored therapy to be obtained, sparing healthy tissue and so minimizing potential damages to at-risk organs. Absorbed dose represents a reliable indicator of biological response due to its correlation to tissue irradiation effects. The present paper aims to focus attention on iodine therapy for DTC treatment and has developed due to the urgent need for standardization in procedures, since no unique approaches are available. This review aims to summarize new proposals for a dosimetry-based therapy and so explore new alternatives that could provide the possibility to achieve more tailored therapies, minimizing the possible side effects of radioiodine therapy for Differentiated Thyroid Cancer.
最常见的甲状腺癌是分化型甲状腺癌(DTC),占病例的95%以上。治疗DTC的一个合适选择是全身给予131碘化钠或碘化钾。它是用于照射甲状腺残余组织、微小DTC、其他不可切除或不完全可切除的DTC或所有上述目的的有效工具。剂量测定是一种有效的工具,可实现量身定制的治疗,保护健康组织,从而将对高危器官的潜在损害降至最低。吸收剂量由于其与组织照射效应的相关性,是生物反应的可靠指标。本文旨在关注用于DTC治疗的碘治疗,由于迫切需要规范程序,因为目前尚无统一的方法,因此撰写了本文。本综述旨在总结基于剂量测定的治疗的新建议,从而探索新的替代方法,这些方法可能提供实现更个性化治疗的可能性,将分化型甲状腺癌放射性碘治疗的可能副作用降至最低。